Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX01 and Pegylated Interferon α-2b in Advanced Indolent B-cell Lymphoma
NCT04246359Phase 2Unknown
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, peginterferon alfa-2b in indolent B-cell lymphoma. Status: unknown.
02
Drugs
rituximabpeginterferon alfa-2b
03
Conditions
indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT04246359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246359.